Acute Kidney Injury (AKI), also referred to as acute renal failure (ARF), is a medical condition marked by azotemia that evolves over a period of hours to days, with or without a decrease in urine output (oliguria). AKI is typically defined as a sudden decline in kidney function, clinically evident as a reversible rise in nitrogenous waste products, specifically blood urea nitrogen (BUN) and serum creatinine levels, within a timeframe of hours to weeks. This condition results in a rapid deterioration in renal performance, leading to the accumulation of metabolic waste, imbalances in electrolytes, and disruptions in fluid volume regulation.

Curious about the numbers? Dive into the data with our infographic: Click Here

Acute Kidney Injury Epidemiology Segmentation in the 7MM

• Total Incident Population of AKI in Hospitalized Patients
  
• Mortality-Adjusted Incident Population of AKI in Hospitalized Patients
  
• Stage-Specific Incident Population of AKI
  
• Age-Specific Incident Population of AKI
  

Acute Kidney Injury Epidemiological Insights Observed in the 7MM

In 2022, the total number of mortality-adjusted incident cases of Acute Kidney Injury across the 7 major markets (7MM) was approximately 14.6 million.

Acute Kidney Injury Market Insight

In 2022, the overall market size for Acute Kidney Injury within the 7MM was estimated at around USD 6.2 billion and is anticipated to grow throughout the forecast period (2024–2034).

Acute Kidney Injury Market Strengths

The AKI drug development pipeline is notably strong, with a wide array of therapeutic candidates contributing to a promising future market landscape.

Acute Kidney Injury Market Opportunities

Clinical evaluations and patient history play a crucial role in identifying the underlying causes of AKI, such as exposure to nephrotoxic agents or systemic conditions. Diagnosis is primarily based on elevated serum creatinine or decreased urine output, supported by additional tests like urinalysis, serum creatinine measurements, and kidney biopsies for a comprehensive assessment.

Acute Kidney Injury Emerging Drugs and Key Companies

• RBT-1 (Renibus Therapeutics)
  
• OCE-205 (Ocelot Bio)
  
• APX-115 (AptaBio Therapeutics)
  
• Ilofotase alfa (AM-Pharma)
  
• bRESCAP (Alloksys Life Sciences)

Download the full infographic to uncover detailed insights: Click Here